. intolerance). Ibrutinib is The present gold regular therapy for people with relapsed/refractory disorder, based upon the final results of numerous phase I-III trials, one hundred fifteen–119 but this is also changing for 2 primary good reasons: (i) a growing proportion of people presently obtain ibrutinib as frontline therapy; and (ii) several